Beranda › Kanker Paru › Colorado
Uji klinis Kanker Paru di Colorado
38 studi untuk Kanker Paru mencari peserta di lokasi di Colorado.
Kota di Colorado
- Aurora19 studi
- Denver16 studi
- Colorado Springs8 studi
- Fort Collins8 studi
- Centennial8 studi
- Loveland7 studi
- Greeley7 studi
- Boulder5 studi
- Highlands Ranch5 studi
- Grand Junction4 studi
Teks studi resmi (Bahasa Inggris)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Rocky Mountain Cancer Centers-Aurora, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Rocky Mountain Cancer Centers-Boulder, Boulder
- dan 13 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Rocky Mountain Cancer Center, Denver
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Rocky Mountain Regional VA Medical Center, Aurora
- UCHealth University of Colorado Hospital, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- dan 15 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Rocky Mountain Cancer Centers-Aurora, Aurora
- Rocky Mountain Cancer Centers-Boulder, Boulder
- Kaiser Permanente-Franklin, Denver
- dan 3 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT04181060Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Kaiser Permanente-Franklin, Denver
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
- Kaiser Permanente-Rock Creek, Lafayette
- dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06498635Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Rocky Mountain Cancer Centers, Boulder
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06765109Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Presbyterian/St Lukes Medical Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07519655This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Intermountain Health Cancer Center Lutheran Hospital, Golden
- Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
- Intermountain Health St. Mary's Regional Hospital, Grand Junction
- dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06758401Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Vail Health, Vail
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Colorado Cancer Center, Aurora
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06128551Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Shaw Cancer Center, Edwards
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07100080Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- University of Colorado - Aurora Cancer Center, Aurora
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05786924A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- UC Health Oncology Research, Colorado Springs
- Poudre Valley Health Care, Inc. d/b/a Poudre Valley Health System, Fort Collins
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Rocky Mountain Cancer Centers, Lone Tree
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- University of Colorado Health Hospital, Aurora
- Sarah Cannon Research Institute at HealthOne, Denver
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06561685AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Denver
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07038343Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- University of Colorado Cancer Center, Aurora
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06343402The Vanguard Study: Testing a New Way to Screen for Cancer
- Keefe Memorial Hospital, Cheyenne Wells
- Kaiser Permanente-Franklin, Denver
- Poudre Valley Hospital, Fort Collins
- dan 5 lainnya
Menerima pesertaSukarelawan sehat diterima
Usia 45 hingga 75 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06995898Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- University of Colorado Health, Aurora
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07185997Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Sarah Cannon Research Institute - Denver DDU, Denver
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT06582017Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
- University of Colorado Hospital, Aurora
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07499674Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- UCHealth University of Colorado Hospital, Aurora
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- UCHealth Memorial Hospital Central, Colorado Springs
- dan 8 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05624996Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- VA Western Colorado Health Care System, Grand Junction
Menerima peserta
Usia 50 hingga 80 · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT07168993A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Sarah Cannon Research Institute at HealthONE, Denver
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT05652686Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Colorado Health Medical Group - Medical Oncology & Hematology, Colorado Springs
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06162221Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- Sarah Cannon, SCRI Oncology Partners - Health One, Denver
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT04678648Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- UCHealth University of Colorado Hospital, Aurora
- UCHealth Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
- dan 5 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Sarah Cannon Research Institute Denver, Denver
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT06922591Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- UCHealth University of Colorado Hospital, Aurora
- UCHealth Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
- dan 4 lainnya
Menerima pesertaFase 2
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
- University of Colorado Cancer Center, Aurora
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Apr 2026 · NCT05987644A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI) at HealthONE, Denver
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mar 2026 · NCT05948865Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
- University of Colorado Cancer Center, Aurora
Menerima pesertaStudi observasional
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT01580982Improving Care for Rural Patients With Solid Tumors
- University of Colorado Hospital, Aurora
- Memorial Hospital Central, Colorado Springs
- Memorial Hospital North, Colorado Springs
- dan 10 lainnya
Menerima peserta
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT04916990Specimen Banking From Patients With Lung Cancer
- University of Colorado Cancer Center, Aurora
Menerima pesertaStudi observasional
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 29 Jan 2026 · NCT01585675Targeted Telerehabilitation Following Curative Intent Therapy of Lung Cancer
- Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jan 2026 · NCT05179408SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Aurora
- Massive Bio SYNERGY-AI site, Denver
- Massive Bio SYNERGY-AI site, Littleton
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- University of Colorado Cancer Center at UC Health Sciences Center, Aurora
Menerima pesertaStudi observasional
Usia 21 hingga 90 · Semua jenis kelamin · Diperbarui 22 Sep 2025 · NCT00900419Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.